Ibandronate sodium
| Status | Commercial |
| Development phase | |
| Therapeutic cat. | Musculo-skeletal |
| Polymorphic form | Monohydrate Form B |
| CAS No. | 138926-19-9 |
| Reference Product | |
| Injectable Form | Injectable |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | |
| Samples |
Drug description
Ibandronate is a bisphosphonate medicine that alters bone formation and breakdown in the body. This can slow bone loss and may help prevent bone fractures. Ibandronate is used to treat or prevent osteoporosis in women after menopause. Ibandronate may also be used for purposes not listed in this medication guide.
Polpharma API
- Long experience in in-house commercial manufacturing
- Extensive portfolio of Bisphosphonates
- Technology not generating genotoxic impurities
- Injection grade
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
